225 related articles for article (PubMed ID: 38584601)
1. Efficacy and safety of PARP inhibitors combined with antiangiogenic agents in the maintenance treatment of ovarian cancer: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials.
Wei Y; He L; Liu T; Guo T; Xie C; Jia J; Lin Y; Liu J; Fan J
Front Pharmacol; 2024; 15():1372077. PubMed ID: 38584601
[No Abstract] [Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
5. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
Tattersall A; Ryan N; Wiggans AJ; Rogozińska E; Morrison J
Cochrane Database Syst Rev; 2022 Feb; 2(2):CD007929. PubMed ID: 35170751
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of PARP inhibitors in the treatment of advanced ovarian cancer: An updated systematic review and meta-analysis of randomized controlled trials.
Hao J; Liu Y; Zhang T; He J; Zhao H; An R; Xue Y
Crit Rev Oncol Hematol; 2021 Jan; 157():103145. PubMed ID: 33254040
[TBL] [Abstract][Full Text] [Related]
7. PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer.
Taylor AM; Chan DLH; Tio M; Patil SM; Traina TA; Robson ME; Khasraw M
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011395. PubMed ID: 33886122
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of anti-CD38 monoclonal antibodies in patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials.
Ye L; Zhou F; Cheng D; Xie M; Yan X; Xue Y; Yang Q; Jia R; Zhong L; Yang L; Zou L; Huang N
Front Oncol; 2023; 13():1240318. PubMed ID: 38144527
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of PARP Inhibitor Combination Therapy in Recurrent Ovarian Cancer: A Systematic Review and Meta-Analysis.
Ren N; Zhang L; Yu J; Guan S; Dai X; Sun L; Ying M
Front Oncol; 2021; 11():638295. PubMed ID: 34485111
[TBL] [Abstract][Full Text] [Related]
10. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
Wiggans AJ; Cass GK; Bryant A; Lawrie TA; Morrison J
Cochrane Database Syst Rev; 2015 May; 2015(5):CD007929. PubMed ID: 25991068
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials.
Shao F; Liu J; Duan Y; Li L; Liu L; Zhang C; He S
Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32096544
[TBL] [Abstract][Full Text] [Related]
12. PARP inhibitor era in ovarian cancer treatment: a systematic review and meta-analysis of randomized controlled trials.
Baradács I; Teutsch B; Váradi A; Bilá A; Vincze Á; Hegyi P; Fazekas T; Komoróczy B; Nyirády P; Ács N; Bánhidy F; Lintner B
J Ovarian Res; 2024 Feb; 17(1):53. PubMed ID: 38409030
[TBL] [Abstract][Full Text] [Related]
13. Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
Alvarez Secord A; O'Malley DM; Sood AK; Westin SN; Liu JF
Gynecol Oncol; 2021 Aug; 162(2):482-495. PubMed ID: 34090705
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials.
Wu YS; Shui L; Shen D; Chen X
Oncotarget; 2017 Feb; 8(6):10703-10713. PubMed ID: 27793044
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of VEGF/VEGFR inhibitors for platinum-resistant ovarian cancer: a systematic review and meta-analysis of randomized controlled trials.
Huang D; Ke L; Cui H; Li S; Sun F
BMC Womens Health; 2024 Jan; 24(1):34. PubMed ID: 38218775
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenesis therapy in ovarian cancer patients: An updated meta-analysis for 15 randomized controlled trials.
Jiang Y; Sun X; Kong B; Jiang J
Medicine (Baltimore); 2018 Aug; 97(34):e11920. PubMed ID: 30142803
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer.
Jiang Y; Zhao J; Zhang L; Tian S; Yang T; Wang L; Zhao M; Yang Q; Wang Y; Yang X
Front Oncol; 2020; 10():954. PubMed ID: 32719741
[No Abstract] [Full Text] [Related]
18. Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis.
Piechotta V; Jakob T; Langer P; Monsef I; Scheid C; Estcourt LJ; Ocheni S; Theurich S; Kuhr K; Scheckel B; Adams A; Skoetz N
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31765002
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and toxicity of angiogenesis inhibitors for ovarian cancer: a meta-analysis of randomized controlled trials.
Guo C; Yan C; Qu L; Du R; Lin J
Arch Gynecol Obstet; 2021 Feb; 303(2):285-311. PubMed ID: 33222040
[TBL] [Abstract][Full Text] [Related]
20. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
